Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 42

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 42
---
 infections, we are considering revising the protocol to include both indications. Driven by data from the
bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability
of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic
joint infections and/or wound infections caused by S. aureus.

Corporate History and Reorganization

Armata was created as a result
of a business combination of AmpliPhi Biosciences Corporation, a bacteriophage development stage company (“AmpliPhi”) with
C3J Therapeutics, Inc. (“C3J”), where Ceres Merger Sub, Inc., a wholly-owned subsidiary of AmpliPhi, merged with
and into C3J (the “Merger”). On May 9, 2019, immediately prior to the closing of the Merger, AmpliPhi changed its name
to Armata Pharmaceuticals, Inc.

C3J’s predecessor, C3
Jian, Inc., was incorporated under the laws of the State of California on November 4, 2005. On February 26, 2016, as part
of a reorganization transaction, C3 Jian, Inc. merged with a wholly-owned subsidiary of C3J, and as part of this process, C3 Jian, Inc.
was converted to a limited liability company organized under the laws of the State of California named C3 Jian, LLC. Prior to the Merger,
C3J was privately held and was financed principally through a series of equity financings.

AmpliPhi was incorporated
under the laws of the State of Washington in March 1989 as a wholly-owned subsidiary of Immunex Corporation and began operations
as an independent company in 1992 as Targeted Genetics Corporation. In January 2011, AmpliPhi completed the acquisition of Biocontrol
Ltd, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using
funding from the sale of our legacy gene therapy assets. In November 2012, AmpliPhi completed the acquisition of Special Phage Holdings
Pty Ltd, a company based in Australia, with the goal of continuing research addressing the rapidly escalating problem of antibiotic resistance
through the development of a series of bacteriophage-based treatments.

<div align='center'>5</div>

Pipeline The following